Several studies with different PD-1/PD-L1 blocking antibodies are ongoing, either at a timepoint when most of the leukemia bulk has been eliminated by prior chemotherapy, in combination with chemotherapy or in combination with hypomethylating agents that upregulate the expression of PD-L1 and antigen presentation on leukemia cells. Here, PDCD1 is linked to leukemia.